Summary
In this episode, BPS and Kenny share their predictions for the biopharma industry in 2025, discussing trends in mergers and acquisitions, the future of neuroscience, the rise of nephrology, the impact of bispecific antibodies in oncology, the role of AI in drug development, innovations in hypertension treatment, and the surge in pharmaceutical advertising. They emphasize the importance of patient empowerment and the need for the industry to continue innovating to improve patient outcomes.
Takeaways
Predictions for 2025 are based on current trends and market pressures.
M&A activity is expected to increase, focusing on de-risked assets.
Neuroscience may see a resurgence, but challenges remain.
Nephrology, particularly IGAN, is gaining attention from big pharma.
Bispecific antibodies are becoming a hot topic in oncology.
AI's role in biopharma is under scrutiny as companies seek tangible results.
Hypertension treatment is on the verge of innovation with new routes of administration.
Digital advertising spend by pharma is expected to reach new heights.
Patient empowerment is crucial in healthcare decision-making.
The industry must continue to innovate to improve patient outcomes.
Share this post